Ovid Therapeutics Inc.
OVID- 1D
- +3.2%
Ovid Therapeutics Inc. in brief
Ovid Therapeutics Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. It was founded in 2014. Its market value was $427 M on 16 October 2026, which makes it the 13,275th largest listed company in the world and the 2,634th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $17 M. It employs about 23 people and Margaret A. Alexander is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol OVID (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Ovid Therapeutics Inc.
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific, therapeutic and commercial opportunities across a range of neurological and psychiatric conditions that have few therapeutic options today, both impacting patients’ lives and creating long-term stockholder value.
From the company's annual report filed with the US SEC: read the report
Ovid Therapeutics Inc. timeline
- 2014
- 🏁· approximateFounded
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 5 May 2017; shares registered for exchange trading on 4 May 2017.
- 2021
- 💰Record revenue of $208 millionFY2021, the highest of the 6 years on record.
Events of Ovid Therapeutics Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,239 (Jan 2020) · #3,451 (Jan 2021) · #3,736 (Jan 2022) · #4,126 (Dec 2022) · #3,420 (Jul 2023) · #3,158 (Jan 2024) · #1,605 (Mar 2026) · #2,504 (Aug 2026) · #2,643 (Oct 2026) · #2,637 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 58.8×
- Price / book
- 3.3×
- Free cash flow yield
- -9.0%
- Net margin
- -240.1%
- Operating margin
- -585.4%
- Return on equity
- -13.3%
- Liabilities / assets
- 13.4%
- Revenue growth
- +1171.9%
- R&D / revenue
- 352.8%
- Revenue per employee
- $315 K
- Profit per employee
- $-757 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $7M | +1171.9% | $-42M | $-17M | -240.1% |
| Dec 2024 | $1M | +46.2% | $-62M | $-26M | -4636.8% |
| Dec 2023 | $0M | -74.0% | $-59M | $-52M | -13420.5% |
| Dec 2022 | $2M | -99.3% | $-56M | $-54M | -3611.3% |
| Dec 2021 | $208M | +1551.2% | $124M | $123M | 58.9% |
| Dec 2020 | $13M | — | $-81M | $-81M | -642.2% |
| Dec 2019 | — | — | $-61M | $-60M | — |
| Dec 2018 | — | — | $-53M | $-52M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-38M | $0M | $-38M | — | — |
| Dec 2024 | $-56M | $0M | $-56M | — | — |
| Dec 2023 | $-46M | $0M | $-46M | $-0.74 | — |
| Dec 2022 | $-55M | $1M | $-56M | $-0.77 | — |
| Dec 2021 | $119M | $0M | $118M | $1.76 | — |
| Dec 2020 | $-52M | $0M | $-52M | $-1.39 | — |
| Dec 2019 | $-51M | $0M | $-51M | — | — |
| Dec 2018 | $-46M | $0M | $-46M | $-2.11 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent report
- Jul 8, 20268-KCurrent reportDirectors or officers changed
- Jun 11, 20268-KCurrent reportShareholder vote
- Jun 3, 20268-KCurrent reportDirectors or officers changed
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent report
- Apr 27, 2026DEF 14AProxy statement
- Apr 20, 20268-KCurrent reportOther events
- Mar 18, 202610-KAnnual report · period to Dec 2025
Official filings of Ovid Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $7 M
- Operating income
- $-42 M
- Net income
- $-17 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $151 M
- Total liabilities
- $20 M
- Total equity
- $131 M
As of December-2025
Top 100 institutional investors in Ovid Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 20,741,234 | — | 10.99% | $52 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 12,050,453 | +1,226,973 (+11.34%) | 6.38% | $30 M | Nov 13, 2026 |
| 3 | Eventide Asset Management, LLC | 11,812,241 | 0 (0.00%) | 6.26% | $29 M | Nov 13, 2026 |
| 4 | Affinity Asset Advisors, LLC | 10,144,562 | 0 (0.00%) | 5.38% | $25 M | Nov 13, 2026 |
| 5 | Vanguard Capital Management LLC | 7,828,361 | +68,247 (+0.88%) | 4.15% | $19 M | Nov 13, 2026 |
| 6 | Balyasny Asset Management L.P. | 7,118,278 | +399,202 (+5.94%) | 3.77% | $18 M | Nov 16, 2026 |
| 7 | Braidwell LP | 6,582,421 | +662,957 (+11.20%) | 3.49% | $16 M | Nov 16, 2026 |
| 8 | State Street Corp | 6,203,161 | -1,697,604 (-21.49%) | 3.29% | $15 M | Nov 12, 2026 |
| 9 | Adage Capital Partners GP, L.L.C. | 6,163,781 | 0 (0.00%) | 3.27% | $15 M | Nov 16, 2026 |
| 10 | Federated Hermes, Inc. | 5,951,666 | 0 (0.00%) | 3.15% | $15 M | Nov 12, 2026 |
| 11 | Silverarc Capital Management, LLC | 5,950,000 | +2,848,871 (+91.87%) | 3.15% | $15 M | Nov 12, 2026 |
| 12 | Ra Capital Management, L.P. | 5,598,200 | -4,902,768 (-46.69%) | 2.97% | $14 M | Nov 16, 2026 |
| 13 | ADAR1 Capital Management, LLC | 4,560,813 | -2,856,666 (-38.51%) | 2.42% | $11 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 4,300,950 | +228,297 (+5.61%) | 2.28% | $11 M | Nov 6, 2026 |
| 15 | Integral Health Asset Management, LLC | 3,500,000 | New | 1.85% | $9 M | Nov 16, 2026 |
| 16 | Point72 Asset Management, L.P. | 2,549,273 | +603,546 (+31.02%) | 1.35% | $6 M | Nov 16, 2026 |
| 17 | Ikarian Capital, LLC | 2,119,704 | -150,000 (-6.61%) | 1.12% | $5 M | Nov 16, 2026 |
| 18 | Vanguard Portfolio Management LLC | 1,666,985 | +636,042 (+61.70%) | 0.88% | $4 M | Nov 13, 2026 |
| 19 | Sphera Funds Management LTD. | 1,600,000 | +247,000 (+18.26%) | 0.85% | $4 M | Nov 16, 2026 |
| 20 | Northern Trust Corp | 1,302,864 | +56,725 (+4.55%) | 0.69% | $3 M | Nov 16, 2026 |
| 21 | Stempoint Capital LP | 1,287,804 | -1,129,479 (-46.73%) | 0.68% | $3 M | Nov 16, 2026 |
| 22 | Vanguard Fiduciary Trust Co | 1,195,586 | +54,833 (+4.81%) | 0.63% | $3 M | Nov 13, 2026 |
| 23 | Rosalind Advisors, Inc. | 1,107,994 | 0 (0.00%) | 0.59% | $3 M | Nov 16, 2026 |
| 24 | Propel Bio Management, LLC | 1,018,721 | -96,817 (-8.68%) | 0.54% | $3 M | Nov 13, 2026 |
| 25 | Atom Investors LP | 1,016,854 | +765,018 (+303.78%) | 0.54% | $3 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Sio Capital Management, LLC | 1,005,334 | 0 (0.00%) | 0.53% | $3 M | Nov 16, 2026 |
| 27 | Nuveen, LLC | 893,254 | 0 (0.00%) | 0.47% | $2 M | Nov 10, 2026 |
| 28 | Ensign Peak Advisors, Inc | 825,852 | -162,232 (-16.42%) | 0.44% | $2 M | Nov 12, 2026 |
| 29 | Wells Fargo & Company/mn | 732,590 | -93,616 (-11.33%) | 0.39% | $2 M | Nov 16, 2026 |
| 30 | UBS Group AG | 711,575 | +252,658 (+55.06%) | 0.38% | $2 M | Nov 10, 2026 |
| 31 | Boothbay Fund Management, LLC | 689,001 | -48,757 (-6.61%) | 0.37% | $2 M | Nov 16, 2026 |
| 32 | Goldman Sachs Group Inc | 614,348 | +281,656 (+84.66%) | 0.33% | $2 M | Nov 16, 2026 |
| 33 | FMR LLC | 575,488 | +536,478 (+1375.23%) | 0.30% | $1 M | Nov 10, 2026 |
| 34 | Charles Schwab Investment Management Inc | 558,341 | +114,299 (+25.74%) | 0.30% | $1 M | Nov 16, 2026 |
| 35 | Wellington Management Group LLP | 550,556 | +447,156 (+432.45%) | 0.29% | $1 M | Nov 16, 2026 |
| 36 | Barclays PLC | 510,623 | +476,503 (+1396.55%) | 0.27% | $1 M | Nov 6, 2026 |
| 37 | Bank Of America Corp /de/ | 482,268 | +72,778 (+17.77%) | 0.26% | $1 M | Nov 16, 2026 |
| 38 | Walleye Capital LLC | 479,083 | New | 0.25% | $1 M | Nov 13, 2026 |
| 39 | Bank of New York Mellon Corp | 451,863 | +35,545 (+8.54%) | 0.24% | $1 M | Nov 5, 2026 |
| 40 | Morgan Stanley | 421,089 | +364,170 (+639.80%) | 0.22% | $1 M | Nov 13, 2026 |
| 41 | Dimensional Fund Advisors LP | 378,968 | -8,799 (-2.27%) | 0.20% | $1 M | Nov 4, 2026 |
| 42 | Two Sigma Investments, LP | 331,445 | -500,933 (-60.18%) | 0.18% | $1 M | Nov 16, 2026 |
| 43 | American Century Companies Inc | 315,023 | +145,641 (+85.98%) | 0.17% | $1 M | Nov 12, 2026 |
| 44 | Informed Momentum Co LLC | 266,204 | +6,573 (+2.53%) | 0.14% | $1 M | Nov 16, 2026 |
| 45 | Panagora Asset Management Inc | 248,628 | New | 0.13% | $1 M | Nov 12, 2026 |
| 46 | Squarepoint Ops LLC | 247,799 | +228,862 (+1208.54%) | 0.13% | $1 M | Nov 9, 2026 |
| 47 | Schonfeld Strategic Advisors LLC | 222,127 | +187,078 (+533.76%) | 0.12% | $1 M | Nov 16, 2026 |
| 48 | Parkman Healthcare Partners LLC | 215,462 | +17,515 (+8.85%) | 0.11% | $1 M | Nov 16, 2026 |
| 49 | Invesco Ltd. | 212,315 | +37,415 (+21.39%) | 0.11% | $1 M | Nov 12, 2026 |
| 50 | SEI Investments Co | 210,671 | +13,986 (+7.11%) | 0.11% | $1 M | Nov 10, 2026 |
| 51 | Rhumbline Advisers | 182,215 | +12,076 (+7.10%) | 0.10% | $0 M | Nov 10, 2026 |
| 52 | CIBC World Market Inc. | 172,820 | -46,031 (-21.03%) | 0.09% | $0 M | Nov 10, 2026 |
| 53 | Stifel Financial Corp | 164,713 | New | 0.09% | $0 M | Nov 12, 2026 |
| 54 | Vanguard Global Advisers, LLC | 142,707 | +72,180 (+102.34%) | 0.08% | $0 M | Nov 13, 2026 |
| 55 | Deutsche Bank AG\ | 130,660 | -18,731 (-12.54%) | 0.07% | $0 M | Nov 6, 2026 |
| 56 | Velan Capital Investment Management LP | 130,000 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 57 | Price T Rowe Associates Inc /MD/ | 125,725 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 58 | Rafferty Asset Management, LLC | 120,483 | -16,291 (-11.91%) | 0.06% | $0 M | Nov 13, 2026 |
| 59 | D. E. Shaw & Co., Inc. | 101,940 | +65,063 (+176.43%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 88,389 | +2,291 (+2.66%) | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Jpmorgan Chase & Co | 82,988 | +19,506 (+30.73%) | 0.04% | $0 M | Nov 12, 2026 |
| 62 | Sovereign Financial Group, Inc. | 80,000 | +50,000 (+166.67%) | 0.04% | $0 M | Nov 12, 2026 |
| 63 | MetLife Investment Management, LLC | 78,564 | -12,023 (-13.27%) | 0.04% | $0 M | Nov 16, 2026 |
| 64 | LPL Financial LLC | 65,131 | +15,031 (+30.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 65 | Alliancebernstein L.P. | 63,130 | -15,130 (-19.33%) | 0.03% | $0 M | Nov 16, 2026 |
| 66 | Citigroup Inc | 59,686 | -131,372 (-68.76%) | 0.03% | $0 M | Nov 4, 2026 |
| 67 | Bridgeway Capital Management, LLC | 55,434 | -40,000 (-41.91%) | 0.03% | $0 M | Nov 16, 2026 |
| 68 | Spark Investment Management LLC | 55,200 | +23,400 (+73.58%) | 0.03% | $0 M | Nov 13, 2026 |
| 69 | Millennium Management LLC | 55,134 | +22,839 (+70.72%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | Empowered Funds, LLC | 51,234 | -40,000 (-43.84%) | 0.03% | $0 M | Nov 13, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 45,161 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 72 | Manufacturers Life Insurance Company, The | 44,424 | +3,514 (+8.59%) | 0.02% | $0 M | Nov 13, 2026 |
| 73 | Profund Advisors LLC | 44,074 | -25,625 (-36.77%) | 0.02% | $0 M | Oct 29, 2026 |
| 74 | BNP Paribas Financial Markets | 43,814 | +19,938 (+83.51%) | 0.02% | $0 M | Nov 12, 2026 |
| 75 | New York State Common Retirement Fund | 35,400 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 76 | Voya Investment Management LLC | 32,419 | +3,141 (+10.73%) | 0.02% | $0 M | Nov 10, 2026 |
| 77 | Susquehanna International Group, LLP | 28,913 | -41,687 (-59.05%) | 0.02% | $0 M | Nov 16, 2026 |
| 78 | Blair William & Co/il | 28,839 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 79 | Abel Hall, LLC | 28,499 | +175 (+0.62%) | 0.02% | $0 M | Oct 19, 2026 |
| 80 | First Manhattan Co. LLC. | 26,000 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 81 | Prudential Financial Inc | 25,945 | +2,850 (+12.34%) | 0.01% | $0 M | Nov 16, 2026 |
| 82 | Fred Alger Management, LLC | 23,721 | New | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Group One Trading LLC | 22,580 | +3,917 (+20.99%) | 0.01% | $0 M | Nov 10, 2026 |
| 84 | Creative Planning | 21,110 | +112 (+0.53%) | 0.01% | $0 M | Nov 2, 2026 |
| 85 | Total Clarity Wealth Management, Inc. | 20,961 | -6,450 (-23.53%) | 0.01% | $0 M | Oct 26, 2026 |
| 86 | StoneX Group Inc. | 20,782 | New | 0.01% | $0 M | Nov 3, 2026 |
| 87 | ProShare Advisors LLC | 20,737 | +688 (+3.43%) | 0.01% | $0 M | Oct 29, 2026 |
| 88 | Victory Capital Management Inc | 20,596 | +1,248 (+6.45%) | 0.01% | $0 M | Nov 10, 2026 |
| 89 | Caitong International Asset Management Co., Ltd | 20,203 | +6,815 (+50.90%) | 0.01% | $0 M | Oct 29, 2026 |
| 90 | Benin Management CORP | 19,000 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 91 | TLS Advisors LLC | 18,858 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 92 | Focus Advisor Solutions, LLC | 17,875 | -2,125 (-10.62%) | 0.01% | $0 M | Nov 10, 2026 |
| 93 | Assenagon Asset Management S.A. | 17,544 | -17,544 (-50.00%) | 0.01% | $0 M | Oct 15, 2026 |
| 94 | Cetera Investment Advisers | 17,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 95 | Legal & General Group Plc | 16,351 | +1,493 (+10.05%) | 0.01% | $0 M | Nov 16, 2026 |
| 96 | CIBC Bancorp USA Inc. | 16,328 | New | 0.01% | $0 M | Nov 13, 2026 |
| 97 | XTX Topco Ltd | 16,265 | -18,075 (-52.64%) | 0.01% | $0 M | Nov 16, 2026 |
| 98 | Royal Bank Of Canada | 15,460 | +10,668 (+222.62%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Xponance LLC | 15,089 | +529 (+3.63%) | 0.01% | $0 M | Nov 3, 2026 |
| 100 | Ameritas Investment Partners, Inc. | 13,896 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Ovid Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.65 M | $15 M | 3.0% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 4.92 M | $13 M | 2.6% | 0.12% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.89 M | $10 M | 2.1% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 3.57 M | $8 M | 1.9% | 0.28% | no change | Jul 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 2.38 M | $5 M | 1.3% | 0.19% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.95 M | $5 M | 1.0% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 1.93 M | $5 M | 1.0% | 0.29% | −33% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.68 M | $4 M | 0.89% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.21 M | $3 M | 0.64% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 613,458 | $2 M | 0.33% | <0.01% | +91% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 646,552 | $1 M | 0.34% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 514,160 | $1 M | 0.27% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 372,024 | $1 M | 0.20% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 286,234 | $1 M | 0.15% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 215,714 | $1 M | 0.11% | <0.01% | +91% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 189,048 | $1 M | 0.10% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 179,955 | $0 M | 0.10% | <0.01% | +118% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 169,022 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 203,812 | $0 M | 0.11% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 165,365 | $0 M | 0.09% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 167,199 | $0 M | 0.09% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 157,253 | $0 M | 0.08% | <0.01% | +118% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 111,400 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 99,542 | $0 M | 0.05% | <0.01% | new | May 31, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 91,234 | $0 M | 0.05% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 88,375 | $0 M | 0.05% | <0.01% | +172% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 78,781 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 94,188 | $0 M | 0.05% | <0.01% | +62% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 83,973 | $0 M | 0.04% | <0.01% | +129% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 66,483 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 72,842 | $0 M | 0.04% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 71,948 | $0 M | 0.04% | <0.01% | +121% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 57,028 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 67,899 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 54,500 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 51,359 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 43,584 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 38,689 | $0 M | 0.02% | <0.01% | +24% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 34,565 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 33,911 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 31,671 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 27,620 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 27,620 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 24,048 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 23,089 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 26,476 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 20,846 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 20,614 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 18,764 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 17,077 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 19,348 | $0 M | 0.01% | <0.01% | +47% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 17,931 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 17,417 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 13,896 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 12,220 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 13,473 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 10,514 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 10,073 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 9,500 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 6,899 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 5,804 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,333 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 5,973 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 3,918 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 3,865 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,901 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,215 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,878 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 1,810 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,377 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 915 | $0 M | <0.01% | <0.01% | +44% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 71 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Ovid Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Charles Ross CarterChief Financial Officer | Grant or award | +50,000 | — | — | 94,375 | Form 4 |
| filed | Bart FriedmanDirector | Grant or award | +8,789 | $2.560 | $22 K | 8,789 | Form 4 |
| filed | Stelios PapadopoulosDirector | Grant or award | +17,578 | $2.560 | $45 K | 217,578 | Form 4 |
| filed | Kevin Joseph FitzgeraldDirector | Grant or award | +17,578 | $2.560 | $45 K | 17,578 | Form 4 |
| filed | Jeremy M. LevinExecutive Chairman, Director | Option exercise | +47,333 | $1.400 | $66 K | 3.74 M | Form 4 |
| filed | Jeffrey A. RonaCBFO | Grant or award | +68,125 | — | — | 156,313 | Form 4 |
| filed | Jeffrey A. RonaCBFO | Sell | -8,541 | $1.450 | $12 K | 88,188 | Form 4 |
| filed | Margaret A. AlexanderPresident and CEO, Director | Sell | -11,656 | $1.450 | $17 K | 61,750 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Ovid Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.15 reverse split in the period to
Fails to deliver
- : 17,077 shares at $2.26
- : 388 shares at $2.19
- : 1,826 shares at $2.34
- : 366 shares at $2.54
- : 4,202 shares at $2.71
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Ovid Therapeutics Inc. scorecard#
Passes 6 of the 17 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 16, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.3×Price to book 3.3× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median58.8×Price to sales 58.8× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-9.0%Free cash flow is -9.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- ✓Revenue up more than 5% a year over three years69.1%69.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median69.1%69.1% a year against Biotechnology's median of 12.9% (181 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✓Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$81 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-585.4%-585.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-17.5%-17.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-585.4%-585.4% in fiscal 2025 against -3703.3% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities9.0×Current ratio 8.97 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone9.29Z-score 9.29 (safe zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Ovid Therapeutics Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -585.4% | -60.5% | |
| Net margin | -240.1% | -68.9% | |
| Return on equity | -17.5% | -61.0% | |
| Revenue growth, 3 years a year | 69.1% | 12.9% | |
| Free cash flow margin | -528.7% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Net loss of $17 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$38 million.
Ovid Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 7.3+1181%100% | 0.6+44.4%100% | 0.4r0.4−73.9%100% | 1.5−99.3%100% | 208+1552%100% | 13—100% | — | — | — | — | |
| Research and development | 26−30.4%353% | 37+28.6%6496% | 29r29+16.1%7293% | 25−47.6%1638% | 47−26.0%22.5% | 63+50.4%503% | 42+24.8%— | 34−32.4%— | 50+421%— | 9.6—— | |
| General and administrative | 24−6.1%332% | 26−17.4%4538% | 31r31−4.2%7930% | 32−12.9%2158% | 37+21.6%17.9% | 31+59.1%243% | 19+0.6%— | 19+27.3%— | 15+16.1%— | 13—— | |
| Operating expenses | 50−20.4%685% | 62+4.7%11034% | 60r60+4.6%15223% | 57−32.2%3796% | 84−10.5%40.4% | 94+53.1%745% | 61+16.0%— | 53−18.6%— | 65+188%— | 23—— | |
| Operating income | −42—−585% | −62—−10934% | −59r−59—−15123% | −56−145%−3696% | 124—59.6% | −81—−645% | −61—— | −53—— | −65—— | −23—— | |
| Interest and finance income | 2.0−48.3%27.9% | 3.9−20.7%692% | 4.9—1260% | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 25−29.4%345% | 35+411%6264% | 6.9r6.9+403%1771% | 1.4—91.8% | −0.0—−0.0% | — | 0.9−0.4%— | 1.0+372%— | 0.2+66.8%— | 0.1—— | |
| Income before tax | −17—−240% | −26—−4670% | −52r−52—−13352% | −54−144%−3605% | 124—59.6% | −81—−642% | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 1.3—0.6% | 0—0.0% | 0—— | 0—— | 0—— | — | |
| Net income attributable to shareholders | −17—−240% | −26—−4670% | −52r−52—−13352% | −54−144%−3605% | 123—58.9% | −81—−642% | −60—— | −52—— | −65—— | −22—— | |
| Earnings per share, basic | — | — | -0.74—— | -0.77−143%— | 1.78—— | -1.39—— | — | -2.11—— | -3.35—— | -2.28—— | |
| Earnings per share, diluted | — | — | -0.74—— | -0.77−144%— | 1.76—— | -1.39—— | — | -2.11—— | -3.35—— | -2.28—— | |
| Shares, weighted average (basic) | — | — | 71+0.2%— | 70+4.4%— | 67+15.4%— | 58—— | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | 71+0.2%— | 70+3.5%— | 68+16.5%— | 58—— | — | 25+27.3%— | 19+96.6%— | 9.8—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 13−50.0%8.7% | 26−2.7%28.5% | 27r27−39.7%18.8% | 45−76.1%28.9% | 188+161%96.5% | 72+71.9%94.9% | 42+14.8%51.8% | 36−58.1%76.6% | 87+67.7%97.4% | 52—97.9% | |
| Short-term investments | 56+111%37.4% | 27−66.0%29.0% | 79r79−6.3%54.7% | 84—54.2% | 0—0.0% | — | 35+595%43.1% | 5.0—10.5% | — | — | |
| Other current assets | 4.7+65.2%3.1% | 2.9−23.9%3.1% | 3.8r3.8+58.2%2.6% | 2.4−11.3%1.5% | 2.7+0.5%1.4% | 2.7+37.3%3.5% | 1.9−10.4%2.4% | 2.2r2.8+48.2%4.5% | 1.5+560%1.6% | 0.2—0.4% | |
| Current assets | 74+32.9%49.3% | 56−49.0%60.7% | 110r110−16.6%76.1% | 131−31.0%84.6% | 190+155%97.9% | 75−6.2%98.6% | 80+80.3%98.7% | 44−50.0%92.9% | 89+69.0%99.0% | 52—98.8% | |
| Property, plant and equipment | 0.3−41.8%0.2% | 0.4−43.7%0.5% | 0.8r0.8−33.0%0.5% | 1.1+373%0.7% | 0.2+79.0%0.1% | 0.1+98.4%0.2% | 0.1−2.2%0.1% | 0.1+34.9%0.1% | 0.1+18.8%0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | 12−9.3%7.7% | 13−7.9%13.9% | 14r14−6.9%9.6% | 15—9.6% | 0—0.0% | — | — | — | — | — | |
| Other intangible assets | 0r0−100%0.0% | 0.1r0.1−50.0%0.1% | 0.2r0.2−10.0%0.1% | 0.2+35.4%0.1% | 0.2r0.2−48.6%0.1% | 0.3r0.3−31.7%0.4% | 0.5+19.1%0.6% | 0.4r0.4+216%0.8% | 0.1+12.8%0.1% | 0.1r0.1—0.2% | |
| Investments in associates | — | — | — | 5.1+219%3.3% | 1.6—0.8% | 0—0.0% | — | — | — | — | |
| Long-term investments | — | 21+19.0%22.8% | 18r18+213%12.2% | 5.6+245%3.6% | 1.6—0.8% | 0—0.0% | — | — | — | — | |
| Total assets | 151+63.8%100% | 92−36.0%100% | 144r144−7.2%100% | 155−20.2%100% | 195+156%100% | 76−6.1%100% | 81+69.7%100% | 48−46.7%100% | 89+68.7%100% | 53—100% | |
| Accounts payable | 2.0−38.7%1.3% | 3.2r3.2−13.8%3.5% | 3.7r3.7+89.6%2.6% | 2.0−72.6%1.3% | 7.1+30.9%3.7% | 5.4+67.3%7.2% | 3.3−13.3%4.0% | 3.8+85.4%7.9% | 2.0+136%2.3% | 0.9—1.6% | |
| Current liabilities | 8.3−21.2%5.5% | 11−8.3%11.4% | 11r11+64.1%8.0% | 7.0−52.8%4.5% | 15−32.9%7.6% | 22+109%29.1% | 11+19.1%13.0% | 8.8+46.9%18.6% | 6.0+61.3%6.7% | 3.7—7.0% | |
| Lease liabilities (non-current) | 12−10.7%7.9% | 13−9.1%14.6% | 15r15−7.8%10.2% | 16—10.3% | 0—0.0% | — | — | — | — | — | |
| Total liabilities | 20−15.3%13.4% | 24−57.4%26.0% | 56r56+145%39.0% | 23+55.4%14.8% | 15−54.2%7.6% | 32+198%42.5% | 11+22.3%13.4% | 8.8—18.6% | — | — | |
| Retained earnings | −322—−213% | −304—−330% | −278r−278—−193% | −226—−145% | −171—−88.1% | −294—−387% | −213—−264% | −153—−320% | −101—−113% | −36—−67.7% | |
| Shareholders' equity | 131+91.5%86.6% | 68−22.3%74.0% | 88r88−33.6%61.0% | 132r132−26.4%85.2% | 180+312%92.4% | 44−37.7%57.5% | 70+80.4%86.6% | 39−53.5%81.4% | 83+69.3%93.3% | 49—93.0% | |
| Total liabilities and equity | 151+63.8%100% | 92−36.0%100% | 144r144−7.2%100% | 155−20.2%100% | 195+156%100% | 76−6.1%100% | 81+69.7%100% | 48−46.7%100% | 89+68.7%100% | 53—100% | |
| Shares outstanding | 130+83.3%— | 71+0.4%— | 71+0.3%— | 70+0.1%— | 70+7.0%— | 66+20.2%— | 55+122%— | 25+0.2%— | 25+150%— | 9.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.3−55.5%3.8% | 0.6+7.9%108% | 0.6r0.6+10.8%145% | 0.5+116%34.1% | 0.2−22.7%0.1% | 0.3+20.3%2.4% | 0.3+79.9%— | 0.1+76.5%— | 0.1+42.1%— | 0.1—— | |
| Share-based compensation | 4.8−23.4%66.3% | 6.3−13.9%1109% | 7.3r7.3+11.1%1858% | 6.6+29.7%436% | 5.1−32.8%2.4% | 7.5+44.6%59.6% | 5.2−26.3%— | 7.1+10.4%— | 6.4+75.7%— | 3.6—— | |
| Cash from operating activities | −38—−529% | −56—−9886% | −46r−46—−11679% | −55−147%−3675% | 119—56.9% | −52—−409% | −51—— | −46—— | −31—— | −18—— | |
| Capital expenditure | 0—0.0% | −0.1—−12.5% | −0.0r−0.0—−10.2% | −1.2—−81.5% | −0.2—−0.1% | −0.1—−1.0% | −0.1—— | −0.0—— | −0.0—— | −0.0—— | |
| Cash from investing activities | −50−191%−687% | 55—9646% | −2.6r−2.6—−658% | −88—−5848% | −1.8−105%−0.9% | 35—275% | −30—— | −5.4—— | −0.0—— | −0.2—— | |
| Shares issued | — | — | — | — | 0−100%0.0% | 47−27.1%370% | 64—— | — | — | — | |
| Cash from financing activities | 75+11991%1037% | 0.6−98.0%110% | 31r31+16802%7790% | 0.2−80.0%12.0% | 0.9−98.1%0.4% | 47−45.6%373% | 87+30144%— | 0.3−99.6%— | 67—— | −0.0—— | |
| Change in cash | −13—−181% | −0.7—−131% | — | −143−221%−9511% | 118+291%56.5% | 30+457%239% | 5.4—— | −51−244%— | 35—— | −18—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.5−78.0%100% | 0−100%— | 0.7−88.3%100% | 0−100%— | 0.7*+845%100% | 0.1−23.7%100% | 6.3+3611%100% | 0.1−12.2%100% | 0.1*−46.5%100% | 0.2—100% | 0.2—100% | 0.1—100% | 0.1r0.1*—100% | |
| Research and development | 43+74.3%2993% | 16+167%— | 10.0+54.0%1358% | 11+67.9%— | 6.6*+11.2%918% | 5.9−25.3%4447% | 6.5−48.6%103% | 6.7−36.0%5122% | 5.9*−44.3%7793% | 7.9—4540% | 13—7445% | 10—7025% | 11r11*—7494% | |
| General and administrative | 26+16.3%1808% | 6.7−1.7%— | 6.5+32.7%883% | 6.7+10.7%— | 6.4*+31.7%894% | 6.8+22.4%5140% | 4.9−39.8%77.8% | 6.0−16.0%4632% | 4.9*−36.6%6414% | 5.5—3205% | 8.1—4795% | 7.2—4843% | 7.7r7.7*—5414% | |
| Operating expenses | 70+46.7%4800% | 22+76.7%— | 16+44.8%2242% | 18+40.7%— | 13*+20.5%1812% | 13−5.6%9587% | 11−45.2%181% | 13−27.8%9754% | 11*−41.1%14208% | 13—7745% | 21—12240% | 18—11868% | 18r18*—12908% | |
| Operating income | −68—−4700% | −22—— | −16—−2142% | −18—— | −12*—−1712% | −13—−9487% | −5.1—−80.9% | −13—−9654% | −11*—−14108% | −13—−7645% | −21—−12140% | −17—−11768% | −18r−18*—−12808% | |
| Interest and finance income | 4.6+154%320% | 1.5+393%— | 1.6+306%213% | 0.7+50.1%— | 0.8*+30.3%118% | 0.3−68.0%230% | 0.4−61.3%6.1% | 0.5−63.0%378% | 0.7*—855% | 0.9—547% | 1.0—586% | 1.3—897% | — | |
| Other non-operating income (expense) | 25+453%1729% | 1.6+334%— | 0.7+77.1%94.0% | 0.9−62.9%— | 22*+1395%3058% | 0.4—277% | 0.4−98.7%6.2% | 2.3−59.5%1781% | 1.5*−48.8%1933% | −0.8—−451% | 29—17182% | 5.7—3867% | 2.9r2.9*—2019% | |
| Income before tax | −43—−2971% | −21—— | −15—−2048% | −17—— | 9.7*—1346% | −12—−9211% | −4.7−155%−74.7% | −10—−7873% | −9.3*—−12175% | −14—−8096% | 8.5—5042% | −12—−7901% | −15r−15*—−10790% | |
| Income tax | 0—0.0% | 0—— | 0—0.0% | 0—— | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income attributable to shareholders | −43—−2971% | −21—— | −15—−2048% | −17—— | 9.7*—1346% | −12—−9211% | −4.7−155%−74.7% | −10—−7873% | −9.3*—−12175% | −14—−8096% | 8.5—5042% | −12—−7901% | −15r−15*—−10790% | |
| Earnings per share, basic | — | — | — | — | — | — | — | — | — | -0.20—— | 0.12—— | -0.17—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | -0.20—— | 0.12—— | -0.17—— | — | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | — | — | 71—— | 71—— | 71—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | 71—— | 71—— | 71—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 14—6.2% | 14−33.0%6.2% | 11−60.1%4.9% | 94+345%41.7% | 13−50.0%8.7% | 21+37.3%32.3% | 28−4.3%36.7% | 21−31.3%25.9% | 26−2.7%28.5% | 15—14.6% | 30—25.1% | 31—23.4% | 27r27—18.8% | |
| Short-term investments | 123—55.3% | 123+2360%55.3% | 106+966%45.6% | 61+181%27.2% | 56+111%37.4% | 5.0−89.5%7.8% | 9.9−79.0%12.8% | 22−63.3%26.8% | 27−66.0%29.0% | 48—46.5% | 47—40.0% | 59—45.2% | 79r79—54.7% | |
| Other current assets | 5.4—2.4% | 5.4+66.3%2.4% | 6.4+71.0%2.8% | 4.6+58.1%2.0% | 4.7+65.2%3.1% | 3.2+3.4%5.0% | 3.7−4.4%4.8% | 2.9+0.5%3.6% | 2.9−23.9%3.1% | 3.1—3.0% | 3.9—3.3% | 2.9—2.2% | 3.8r3.8—2.6% | |
| Current assets | 142—63.9% | 142+392%63.9% | 124+194%53.3% | 160+249%71.0% | 74+32.9%49.3% | 29−56.2%45.1% | 42−48.0%54.4% | 46−50.7%56.2% | 56−49.0%60.7% | 66—64.1% | 81—68.5% | 93—70.8% | 110r110—76.1% | |
| Property, plant and equipment | 0.2—0.1% | 0.2−30.9%0.1% | 0.2−29.5%0.1% | 0.2−37.3%0.1% | 0.3−41.8%0.2% | 0.3−47.2%0.4% | 0.3−53.9%0.4% | 0.3−49.6%0.4% | 0.4−43.7%0.5% | 0.5—0.5% | 0.6—0.5% | 0.7—0.5% | 0.8r0.8—0.5% | |
| Right-of-use (leased) assets | 11—4.8% | 11−10.6%4.8% | 11−10.1%4.7% | 11−9.7%5.0% | 12−9.3%7.7% | 12−8.9%18.7% | 12−8.5%15.8% | 13−8.2%15.3% | 13−7.9%13.9% | 13—12.7% | 13—11.3% | 14—10.4% | 14r14—9.6% | |
| Other intangible assets | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0r0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.0−74.3%0.0% | 0.1r0.1−50.0%0.1% | 0.2—0.2% | 0.2—0.2% | 0.1—0.1% | 0.2r0.2—0.1% | |
| Long-term investments | — | — | — | — | — | 21−1.0%32.7% | 21−0.7%27.0% | 21−5.1%25.6% | 21+19.0%22.8% | 21—20.6% | 21—17.8% | 22—16.7% | 18r18—12.2% | |
| Total assets | 222—100% | 222+248%100% | 232+200%100% | 226+176%100% | 151+63.8%100% | 64−37.8%100% | 77−34.4%100% | 82−38.0%100% | 92−36.0%100% | 103—100% | 118—100% | 132—100% | 144r144—100% | |
| Accounts payable | 5.9—2.6% | 5.9+242%2.6% | 4.1+3.1%1.8% | 8.9+355%3.9% | 2.0−38.7%1.3% | 1.7−36.9%2.7% | 4.0−16.3%5.1% | 2.0−45.8%2.4% | 3.2r3.2−13.8%3.5% | 2.7—2.6% | 4.7—4.0% | 3.6—2.7% | 3.7r3.7—2.6% | |
| Current liabilities | 12—5.3% | 12+74.5%5.3% | 10.0+11.8%4.3% | 16+69.2%7.0% | 8.3−21.2%5.5% | 6.8−41.6%10.6% | 8.9−36.8%11.5% | 9.3+4.5%11.4% | 11−8.3%11.4% | 12—11.3% | 14—12.0% | 8.9—6.8% | 11r11—8.0% | |
| Lease liabilities (non-current) | 11—4.9% | 11−12.2%4.9% | 11−11.7%4.8% | 12−11.2%5.1% | 12−10.7%7.9% | 12−10.2%19.3% | 13−9.8%16.4% | 13−9.4%16.0% | 13−9.1%14.6% | 14—13.4% | 14—11.9% | 14—11.0% | 15r15—10.2% | |
| Total liabilities | 24—10.6% | 24+23.1%10.6% | 22+2.1%9.5% | 27+22.3%12.1% | 20−15.3%13.4% | 19−27.4%30.0% | 22−25.9%27.9% | 22−58.0%27.4% | 24−57.4%26.0% | 26—25.7% | 29—24.7% | 53—40.5% | 56r56—39.0% | |
| Retained earnings | −374—−169% | −374—−169% | −354—−152% | −339—−150% | −322—−213% | −331—−519% | −319—−412% | −315—−385% | −304—−330% | −295—−287% | −281—−238% | −290—−220% | −278r−278—−193% | |
| Shareholders' equity | 199—89.4% | 199+344%89.4% | 210+276%90.5% | 198+234%87.9% | 131+91.5%86.6% | 45−41.4%70.0% | 56−37.2%72.1% | 59−24.3%72.6% | 68−22.3%74.0% | 76—74.3% | 89—75.3% | 78—59.5% | 88r88—61.0% | |
| Total liabilities and equity | 222—100% | 222+248%100% | 232+200%100% | 226+176%100% | 151+63.8%100% | 64−37.8%100% | 77−34.4%100% | 82−38.0%100% | 92−36.0%100% | 103—100% | 118—100% | 132—100% | 144r144—100% | |
| Shares outstanding | 189—— | 189+165%— | 185+160%— | 167+135%— | 130+83.3%— | 71+0.2%— | 71+0.2%— | 71+0.5%— | 71+0.4%— | 71—— | 71—— | 71—— | 71—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−80.0%5.7% | 0.0*−6.3%— | 0.0*−83.8%2.2% | 0.0−75.2%— | 0.0*−89.4%2.4% | 0.0*−90.5%12.1% | 0.1*−33.1%1.6% | 0.1+3.7%108% | 0.2*+14.3%211% | 0.2*—97.7% | 0.1*—87.6% | 0.1—91.9% | 0.1r0.1*—98.6% | |
| Share-based compensation | 4.9+1.6%341% | 1.3+15.2%— | 1.4+17.4%195% | 1.0−18.5%— | 1.2*−5.2%166% | 1.1−15.3%839% | 1.2−29.9%19.4% | 1.3−34.8%988% | 1.3*−29.6%1658% | 1.3—756% | 1.7—1030% | 2.0—1330% | 1.8r1.8*—1260% | |
| Cash from operating activities | −58—−3982% | −16*—— | −18*—−2400% | −14—— | −10*—−1450% | −13*—−9752% | −4.8*—−76.1% | −10—−7908% | −10*—−13168% | −15*—−8675% | −14*—−8435% | −17—−11274% | −12r−12*—−8388% | |
| Capital expenditure | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.0*—−28.9% | — | −0.0*—−20.1% | −0.0—−12.8% | −0.0r−0.0*—−9.2% | |
| Cash from investing activities | −142−426%−9766% | 11*+121%— | −87*−820%−11834% | 6.0+16.6%— | −72*−438%−10036% | 5.1*+1630%3828% | 12*−6.0%192% | 5.1−74.7%3925% | 21*—28016% | 0.3*—169% | 13*—7587% | 20—13641% | −49r−49*—−34166% | |
| Shares issued | — | 8.1*—— | 0.0*—0.1% | 2.4—— | — | 0*—0.0% | 0*—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from financing activities | 193+689329%13304% | 7.3*+48420%— | 22*—2947% | 89+684377%— | 75*—10471% | 0.0*−60.5%11.4% | 0*−100%0.0% | 0.0−94.3%10.0% | 0*−100%0.0% | 0.0*—22.0% | 0.4*—211% | 0.2—154% | 30r30*—21150% | |
| Change in cash | −6.8—−469% | 2.5*—— | −83*−1237%−11287% | 81—— | −7.5*—−1039% | −7.8*—−5912% | 7.3*—116% | −5.2—−3973% | — | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Ovid Therapeutics Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$7 M100%+1172%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Ovid Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Levin | $1.9 M | $3.7 M | $996 K | $88 |
| 2024Margaret A. Alexander | $2.8 M | $36 K | $1.6 M | $29 |
| 2023Margaret A. Alexander | $2.1 M | $3.0 M | $1.1 M | $100 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Ovid Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 6 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Ovid Therapeutics Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2023.
Lobbying firms hired in 2023
THE KPM GROUP DC LLC $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2023 | $20 K | — | 1 |
| 2022 | $80 K | — | 4 |
| 2021 | $84 K | — | 4 |
| 2020 | $30 K | — | 4 |
| 2019 | $0 | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Ovid Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Ovid Therapeutics Inc.#
1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $160 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Program ManagementMedical Scientists, Except Epidemiologists | 1 | $160 K |
Where: Boston, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 1 | 1 | $160 K | 1 |
| FY2021 | 2 | 2 | $290 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as OVID THERAPEUTICS INC.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | 17 | · | · | · | · | · | · | 17 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 17 people (43% of workforce) | Restructuring planSEC 8-K | “The Company will reduce its workforce by 17 people, or approximately 43% of the Company’s existing headcount, to preserve cash resources.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Ovid Therapeutics Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 10 November 2026automatic update · Nov 10, 2026
Ovid Therapeutics Inc. announced results on 10 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $21 million.
- Mutual funds: 70 funds hold $84 millionautomatic update · Jul 31, 2026
70 mutual funds in 1 country hold shares of Ovid Therapeutics Inc. worth $84 million, about 17.3% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 66 funds added shares and 2 sold; on balance they bought $46 million. Share splits are not counted as trading.
How Ovid Therapeutics Inc. compares in Biotechnology
- Market cap$427 M · higher than 55% of 726
- Revenue$7 M · higher than 39% of 647
- Net margin-240.1% · higher than 24% of 408
- Revenue growth1171.9% · higher than 98% of 438
- Price / sales58.8× · lower than 16% of 339
- Price / book3.3× · lower than 45% of 534
- FCF yield-9.0% · higher than 60% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Ovid Therapeutics Inc.🇺🇸 | $427 M | — | -240.1% | +1171.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 16, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Ovid Therapeutics Inc.? Verify and update this profile — free
Show Ovid Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.